Cidara Therapeutics (NASDAQ:CDTX - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $6.00 price objective on the biotechnology company's stock. HC Wainwright's target price points to a potential upside of 460.75% from the stock's previous close.
Cidara Therapeutics Stock Performance
NASDAQ CDTX traded down $0.09 during trading on Monday, hitting $1.07. The stock had a trading volume of 1,398,390 shares, compared to its average volume of 647,210. The company has a market capitalization of $96.96 million, a PE ratio of -2.74 and a beta of 0.98. The company's 50-day moving average price is $0.75 and its two-hundred day moving average price is $0.78. Cidara Therapeutics has a 12 month low of $0.59 and a 12 month high of $1.48.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in CDTX. Schonfeld Strategic Advisors LLC acquired a new position in shares of Cidara Therapeutics during the 1st quarter worth approximately $846,000. BlackRock Inc. grew its holdings in Cidara Therapeutics by 459.9% in the 1st quarter. BlackRock Inc. now owns 741,713 shares of the biotechnology company's stock valued at $942,000 after buying an additional 609,247 shares in the last quarter. Millennium Management LLC grew its holdings in Cidara Therapeutics by 724.1% in the 4th quarter. Millennium Management LLC now owns 689,917 shares of the biotechnology company's stock valued at $522,000 after buying an additional 606,201 shares in the last quarter. GSA Capital Partners LLP grew its holdings in Cidara Therapeutics by 294.6% in the 4th quarter. GSA Capital Partners LLP now owns 540,446 shares of the biotechnology company's stock valued at $429,000 after buying an additional 403,472 shares in the last quarter. Finally, XTX Topco Ltd grew its holdings in Cidara Therapeutics by 201.8% in the 2nd quarter. XTX Topco Ltd now owns 449,138 shares of the biotechnology company's stock valued at $508,000 after buying an additional 300,303 shares in the last quarter. 35.82% of the stock is owned by institutional investors and hedge funds.
Cidara Therapeutics Company Profile
(
Get Free Report)
Cidara Therapeutics, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
Featured Stories
Before you consider Cidara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cidara Therapeutics wasn't on the list.
While Cidara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
